New York City, New York Oct 17, 2022 (Issuewire.com) - On October 12-14, 2022, Creative Biolabs attended the 10th Annual Immuno-Oncology Summit held by Cambridge Healthtech Institute (CHI), a great event focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline.
At booth #9, the scientist representatives met with some familiar faces and more new ones, re-connected with researchers and business partners, and showcased the latest oncolytic virus-related services to visitors.
For oncolytic virus construction, scientists at Creative Biolabs have established a specified oncolytic virus construction process for different kinds of species, such as Adenovirus, Herpes Simplex Virus, Measles Virus, Vaccinia Virus, Vesicular Stomatitis Virus, Adeno-Associated Virus.
For oncolytic virus engineering, Creative Biolabs provides an in-depth optimization of the oncolytic virus to enhance the tumor targeting, tumor lysis, and the effectiveness of priming anticancer immunity.
For oncolytic virus validation, the scientist team is proficient in designing in vitro and in vivo validation studies for each developed oncolytic virus based upon the properties of targeting disease, characteristics of the virus, mechanism of actions, and so on.
For disease-specific oncolytic virotherapy development, relying on the well-established OncoVirapy™ platform, scientists of Creative Biolabs keep devoting endless effort to the development of immunotherapy strategies and reagents aiming at specific categories and features of various cancers, and are now developing immunotherapy for melanoma, genitourinary malignancies, hepatocellular carcinoma, breast cancer, head and neck cancer, brain cancer, mesothelioma, etc.
“We are very enlightened during the summit, especially the talks on Combination Immunotherapies for Cancer. Some new clinical findings proved the potential of oncolytic viruses in tumor treatment and make us more confident in discovering novel oncolytic virotherapy. We will keep exploring and innovating to improve our oncolytic virus-related services and expand the list of pre-made oncolytic virus products, supporting the pursuit of a healthier world of global researchers.” said an on-site scientist from Creative Biolabs.
The next event on Creative Biolabs’ 2022 schedule is the Antibody Engineering & Therapeutics (US) on December 4-8. The specialists will wait for clients with exquisite gifts at Booth #418, and be excited to discuss how Creative Biolabs can help develop and optimize the ongoing or next projects of worldwide clients.
Detailed information about the oncolytic virus development platforms and services can be found at https://www.creative-biolabs.com/oncolytic-virus.
About Creative Biolabs
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is dedicated to offering comprehensive, end-to-end oncolytic virus therapy development services. The whole pipeline covers oncolytic virus engineering, the vitro validation study, in vivo preclinical study, disease-specific oncolytic virotherapy development, etc.
Media Contact
Candy Swift marketing@creative-biolabs.com https://www.creative-biolabs.com/oncolytic-virus
